Table 2. Clinical trials that target TSLP.
| Study title | Reference | Identifier | Stage* | Drug | Disease | Status |
|---|---|---|---|---|---|---|
| A study to evaluate the pharmacokinetics of MEDI9929 (AMG 157) in adolescents with mild to moderate asthma | (178) | NCT02512900 | I | Tezepelumab | Asthma | Completed |
| Study to evaluate the pharmacokinetics of tezepelumab in children with asthma (TRAILHEAD) | (179) | NCT04673630 | I | Tezepelumab | Asthma | Recruiting |
| Double-blind, multiple dose study in subjects with mild atopic asthma | (180) | NCT01405963 | I | Tezepelumab | Asthma | Completed |
| Safety study of AMG 157 in healthy subjects and subjects with atopic dermatitis | (181) | NCT00757042 | I | Tezepelumab | Healthy/AD | Completed |
| Study to evaluate the efficacy and safety of MEDI9929 (AMG 157) in adult subjects with inadequately controlled, severe asthma | (182) | NCT02054130 | II | Tezepelumab | Asthma | Completed |
| Effects of anti-TSLP in patients with asthma (UPSTREAM) | (183) | NCT02698501 | II | Tezepelumab | Asthma | Completed |
| Study to evaluate tezepelumab on airway inflammation in adults with uncontrolled asthma (CASCADE) (CASCADE) | (184) | NCT03688074 | II | Tezepelumab | Asthma | Completed |
| Phase 2a study to evaluate the efficacy and safety of MEDI9929 in adults with atopic dermatitis (ALLEVIAD) | (185) | NCT02525094 | II | Tezepelumab | AD | Completed |
| Anti-TSLP (AMG 157) plus antigen-specific immunotherapy for induction of tolerance in individuals with cat allergy | (186) | NCT02237196 | I/II | Tezepelumab | Cat allergy/cat hypersensitivity | Completed |
| Study to evaluate tezepelumab in adults with chronic spontaneous urticaria (INCEPTION) | (187) | NCT04833855 | II | Tezepelumab | Chronic spontaneous urticaria | Recruiting |
| Tezepelumab COPD exacerbation study (COURSE) | (188) | NCT04039113 | II | Tezepelumab | COPD | Recruiting |
| Study to evaluate tezepelumab in adults & adolescents with severe uncontrolled asthma (NAVIGATOR) | (189) | NCT03347279 | III | Tezepelumab | Asthma | Completed |
| Study to evaluate the efficacy and safety of tezepelumab in reducing oral corticosteroid use in adults with oral corticosteroid dependent asthma (SOURCE) | (190) | NCT03406078 | III | Tezepelumab | Asthma | Completed |
| Long-term safety of tezepelumab in japanese subjects with inadequately controlled severe asthma (NOZOMI) | (191) | NCT04048343 | III | Tezepelumab | Asthma | Completed |
| Extension study to evaluate the safety and tolerability of tezepelumab in adults and adolescents with severe, uncontrolled asthma (DESTINATION) | (192) | NCT03706079 | III | Tezepelumab | Asthma | On going (active) |
| Study to evaluate tezepelumab in adults with severe uncontrolled asthma (DIRECTION) | (193) | NCT03927157 | III | Tezepelumab | Asthma | Recruiting |
| Efficacy and safety of tezepelumab in participants with severe chronic rhinosinusitis with nasal polyposis (WAYPOINT) | (194) | NCT04851964 | III | Tezepelumab | CRS with NP | Recruiting |
| A bronchoprovocation study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of CSJ117 in adult subjects with mild atopic asthma | (195) | NCT03138811 | I | CSJ117 | Asthma | Completed |
| Study of efficacy and safety of CSJ117 in patients with severe uncontrolled asthma | (196) | NCT04410523 | II | CSJ117 | Asthma | Recruiting |
| Study of safety of CSJ117 in participants with moderate to severe uncontrolled asthma | (197) | NCT04946318 | II | CSJ117 | Asthma | Recruiting |
| Study of effect of CSJ117 on symptoms, pharmacodynamics and safety in patients with COPD | (198) | NCT04882124 | II | CSJ117 | COPD | Recruiting |
NP, nasal polyp.
*Stage I, II, and III represent phase 1, phase 2, and phase 3 respectively.